Sarah Cannon Oncology Research Consortium

Sarah Cannon Research Institute (SCRI) is a premier global oncology research organization dedicated to advancing therapies for cancer patients. Operating as a clinical research site network and contract research organization, SCRI conducts community-based clinical trials across the United States and United Kingdom. The organization has played a pivotal role in the development of over 70% of FDA-approved cancer therapies since its inception. In 2022, SCRI entered a joint venture with McKesson's US Oncology Research to expand its clinical trial reach and capabilities. Its comprehensive services include drug development, trial management, and personalized medicine through molecular profiling. The institute's mission is to provide patients with access to innovative treatments closer to home while accelerating the search for a cure.